Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dronabinol and Clonidine for Cannabis Dependence in Schizophrenia
NCT01598896Phase 3Terminated
- Sponsor
- McLean Hospital
- Start
- May 2012
- Primary completion
- Aug 2017
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dronabinol and Clonidine Lauriad in cannabis use disorder (CUD) (2 arms), sponsored by McLean Hospital. Primary endpoint: Change From Baseline in Cannabis Use at 10 Weeks. Started May 2012; status: terminated.
02
Drugs
dronabinolClonidine Lauriad
03
Conditions
cannabis use disorder (CUD)
Beyond the preview
Go deeper on NCT01598896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01598896.